186 related articles for article (PubMed ID: 14674703)
21. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.
Cao Z; Burrell LM; Tikkanen I; Bonnet F; Cooper ME; Gilbert RE
Kidney Int; 2001 Aug; 60(2):715-21. PubMed ID: 11473654
[TBL] [Abstract][Full Text] [Related]
22. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats.
Pu Q; Schiffrin EL
Am J Hypertens; 2001 Oct; 14(10):1067-72. PubMed ID: 11710787
[TBL] [Abstract][Full Text] [Related]
23. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat.
Ferrario CM; Averill DB; Brosnihan KB; Chappell MC; Iskandar SS; Dean RH; Diz DI
Kidney Int; 2002 Oct; 62(4):1349-57. PubMed ID: 12234305
[TBL] [Abstract][Full Text] [Related]
24. Renal effects of omapatrilat and captopril in salt-loaded, nitric oxide-deficient rats.
Ying L; Flamant M; Vandermeersch S; Boffa JJ; Chatziantoniou C; Dussaule JC; Chansel D
Hypertension; 2003 Nov; 42(5):937-44. PubMed ID: 14569001
[TBL] [Abstract][Full Text] [Related]
25. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats.
Elmarakby AA; Morsing P; Pollock JS; Pollock DM
Vascul Pharmacol; 2003 Dec; 40(5):253-9. PubMed ID: 15259792
[TBL] [Abstract][Full Text] [Related]
26. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
[TBL] [Abstract][Full Text] [Related]
27. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11.
Raut R; Rouleau JL; Blais C; Gosselin H; Molinaro G; Sirois MG; Lepage Y; Crine P; Adam A
Am J Physiol; 1999 May; 276(5):H1769-79. PubMed ID: 10330262
[TBL] [Abstract][Full Text] [Related]
28. Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptor blocker.
Wang CH; Leung N; Lapointe N; Szeto L; Uffelman KD; Giacca A; Rouleau JL; Lewis GF
Circulation; 2003 Apr; 107(14):1923-9. PubMed ID: 12668518
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo.
Bäcklund T; Palojoki E; Grönholm T; Eriksson A; Vuolteenaho O; Laine M; Tikkanen I
Pharmacol Res; 2001 Nov; 44(5):411-8. PubMed ID: 11712872
[TBL] [Abstract][Full Text] [Related]
30. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
[TBL] [Abstract][Full Text] [Related]
31. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
[TBL] [Abstract][Full Text] [Related]
32. [Activation of the cardiac angiotensin-converting enzyme after myocardial infarction and its role in ventricular remodeling].
Mill JG; Milanez Mda C; Busatto VC; de Moraes AC; Gomes Mda G
Arq Bras Cardiol; 1997 Aug; 69(2):101-10. PubMed ID: 9567332
[TBL] [Abstract][Full Text] [Related]
33. Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake.
Azizi M; Lamarre-Cliche M; Labatide-Alanore A; Bissery A; Guyene TT; Ménard J
J Am Soc Nephrol; 2002 Oct; 13(10):2454-63. PubMed ID: 12239234
[TBL] [Abstract][Full Text] [Related]
34. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension.
Quaschning T; d'Uscio LV; Shaw S; Lüscher TF
Hypertension; 2001 Apr; 37(4):1108-13. PubMed ID: 11304511
[TBL] [Abstract][Full Text] [Related]
35. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
Loch D; Hoey A; Brown L
Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
[TBL] [Abstract][Full Text] [Related]
36. The cardiovascular actions of omapatrilat in spontaneously hypertensive rats.
Dong Y; Zhou H; Shaffer E; Atamas N; Liao WC; Wei C
Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S1-5. PubMed ID: 11716799
[TBL] [Abstract][Full Text] [Related]
37. Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats.
de Resende MM; Kauser K; Mill JG
Life Sci; 2006 May; 78(26):3066-73. PubMed ID: 16413583
[TBL] [Abstract][Full Text] [Related]
38. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
[TBL] [Abstract][Full Text] [Related]
39. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
Xu J; Carretero OA; Liu YH; Yang F; Shesely EG; Oja-Tebbe N; Yang XP
J Card Fail; 2004 Feb; 10(1):83-9. PubMed ID: 14966779
[TBL] [Abstract][Full Text] [Related]
40. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure.
Burrell LM; Farina NK; Balding LC; Johnston CI
Hypertension; 2000 Dec; 36(6):1105-11. PubMed ID: 11116133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
